Sun Pharmaceutical Industries Board Recommends ₹5 Dividend As Q4 Profit Rises 26%
- By Kotak News Desk
- 23 May 2026 at 12:44 PM IST
- Stock News
- 4m
Stay updated with the latest stock market developments and trends.
You can set Kotak Neo as a preferred source to receive regular market updates.
Sun Pharmaceutical Industries reported a 26% YoY rise in Q4FY26 net profit to ₹2,714 crore, while revenue grew 13%. The board also recommended a final dividend of ₹5 per equity share.
Sun Pharmaceutical on Friday posted a consolidated net profit of ₹2,714 crore for the quarter ended March 2026, registering a 26% rise from ₹2,150 crore reported in the same period last year. The company’s revenue for Q4FY26 also grew 13% year-on-year to ₹14,612 crore, compared with ₹12,959 crore in the corresponding quarter of the previous fiscal.
On a sequential basis, however, the drugmaker’s performance weakened. Profit after tax declined 19% from ₹3,369 crore recorded in Q3FY26, while revenue slipped 6% from ₹15,520 crore posted in the October–December quarter.
At the close of the day on 22 May 2026, Sun Pharmaceutical Industries share price was down by 2.47% to ₹1,844.60 on the National Stock Exchange. Despite the weakness, the stock has still advanced around 10% over the past month and continues to remain positive on a year-to-date basis.
Key Financial Highlights
Total Income | ₹15,070.3 crore | ₹13,571.7 crore | 11.0% |
Total Expenses | ₹11,518.9 crore | ₹9,955.7 crore | 15.7% |
Other Comprehensive Income | ₹1,503.4 crore | ₹335.3 crore | 348.3% |
Total Comprehensive Income | ₹4,213.0 crore | ₹2,489.3 crore | 69.2% |
EPS (Basic & Diluted) | ₹11.3 | ₹9.0 | 25.6% |
R&D Expenses | ₹950.0 crore | ₹790.4 crore | 20.2% |
Other Key Highlights
Other Operating Revenue | ₹52.0 crore | ₹143.3 crore | -63.7% |
Other Income | ₹458.5 crore | ₹612.9 crore | -25.2% |
Employee Benefits Expense | ₹2,960.4 crore | ₹2,488.5 crore | 19.0% |
Finance Costs | ₹85.9 crore | ₹49.1 crore | 74.8% |
Depreciation & Amortisation | ₹775.5 crore | ₹663.8 crore | 16.8% |
Other Expenses | ₹5,322.8 crore | ₹4,408.3 crore | 20.7% |
Also Read - NSE To Remove Exide, Nuvama Wealth From F&O Segment Effective 29 July 2026
Dividend Highlight
The board has recommended a final dividend of ₹5 per equity share with a face value of ₹1 each, subject to shareholders’ approval at the company’s 34th Annual General Meeting (AGM). Following approval, the dividend will be distributed within the timeline specified under the Companies Act, 2013.
Sources
Economic Times
Q4 Financial Report
This article is for informational purposes only and should not be considered investment advice from Kotak Neo. For compliance T&C and disclaimers, visit www.kotakneo.com/disclaimer.
Kotak News Desk brings you latest updates, expert insights, and market-ready ideas - helping you stay informed and invest smarter.
Connect on: Linkedin
0 people liked this article.
